BioAtla, Inc. (BCAB)
NASDAQ: BCAB · Real-Time Price · USD
0.4090
+0.0180 (4.60%)
At close: May 30, 2025, 4:00 PM
0.4230
+0.0140 (3.42%)
After-hours: May 30, 2025, 6:10 PM EDT
BioAtla Revenue
BioAtla had revenue of $11.00M in the twelve months ending March 31, 2025. In the year 2024, BioAtla had annual revenue of $11.00M.
Revenue (ttm)
$11.00M
Revenue Growth
n/a
P/S Ratio
1.90
Revenue / Employee
$180,328
Employees
61
Market Cap
23.89M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
BCAB News
- 25 days ago - BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 25 days ago - BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress - GlobeNewsWire
- 4 weeks ago - BioAtla to Participate in the Citizens Life Sciences Conference - GlobeNewsWire
- 4 weeks ago - BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025 - GlobeNewsWire
- 5 weeks ago - BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire
- 5 weeks ago - BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 2 months ago - BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioAtla Cuts 30% of Jobs in Restructuring Effort - Market Watch